Released Nov 2, 2023, before the open
10-Q filed Nov 2, 2023, 33 days after period end · 0001628280-23-036187
Q3 2023 · 10-Q
Revenue$17.48M$17.48M +163.5% vs Q3 2022+212.2% vs Q2 2023
Net Income-$14.35M-$14.35M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.34-$0.34 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$17,081,000N/M
Operating Cash Flowderived-$27,210,000N/M
Free Cash Flowderived-$27,292,000N/M
Margins · derived
Operating margin-97.7%+328.2 pt vs Q3 2022
Net margin-82.1%+306.4 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $17.48M | $6.63M | $41.00K | $179.00K |
| Net Income | -$14.35M | -$25.77M | -$26.08M | -$18.37M |
| EPS Diluted | -$0.34 | -$0.62 | -$0.71 | -$3.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR